Mergers & Acquisitions

Amgen has agreed to acquire Rodeo Therapeutics, a Seattle, Washington-based biopharmaceutical developing small-molecule therapies, in a $721-million deal ($55 million upfront and future contingent milestone payments potentially worth up to…

As part of an ongoing divestment program of non-core assets following its $62-billion acquisition of Shire in 2019, Takeda Pharmaceutical has completed three divestments totaling approximately $4.1billion. $2.2-Bn Deal with…

Takeda has agreed to acquire Maverick Therapeutics, a Brisbane, California-based biopharmaceutical company specializing in bispecific T-cell-targeted immunotherapies. for $525 million. The acquisition follows a multi-year collaboration between Takeda and Maverick…

Amgen has agreed to acquire Five Prime Therapeutics, a South San Francisco, California-based clinical-stage biopharmaceutical company developing immuno-oncology and targeted cancer therapies, for approximately $1.9 billion. Five Prime’s lead asset,…

Perrigo has agreed to sell its generic prescription pharmaceuticals business to Altaris Capital Partners, an investment firm, for $1.55 billion, which includes $1.5 billion in cash. Perrigo first announced plans…

Merck & Co. has agreed to acquire Pandion Therapeutics, a Watertown, Massachusetts-based company developing therapeutics for autoimmune diseases, for an approximate total equity value of $1.85 billion. Pandion is advancing…